Global healthcare company Baxter International opened its first biologics facility in Asia on Thursday.
It also announced plans for a new processing suite, which will be its second here.
The company said in a statement that this "strengthens Baxter's leadership in hemophilia (a bleeding disorder) and underscores its commitment to increasing access to therapy and improving standards of care for hemophilia patients globally".
The facility and new suite are expected to create 450 biopharmaceutical jobs by next year.
"Baxter's expansion of its biologics footprint in Singapore reinforces our position as a leading biologics hub, with nine facilities which will employ over 2,000 people at steady state," said Mr Yeoh Keat Chuan, managing director at the Singapore Economic Development Board, who officiated the opening ceremony.
He added that the biologics sector supports knowledge intensive and high value added activities which create good jobs for Singaporeans.